Trial By Error: My Follow-up Letter to Mahana Therapeutics’ CEO

By David Tuller, DrPH Last week, I wrote to Rob Paull, the co-founder and CEO of Mahana Therapeutics, regarding the company’s misleading claims about the web-based cognitive behavior therapy program for irritable bowel syndrome it recently licensed from King’s College London. I have also written to Professor Rona Moss-Morris, the co-lead investigator of ACTIB, the […]

Source link

Related posts

Genomic Mechanisms of Physiological and Morphological Adaptations of Limestone Langurs to Karst Habitats


Local Boston Hair Transplantation Clinic Redefines Cosmetic Hair Restoration With Breakthrough, Artificial Technology


Long Noncoding RNA FAM83H-AS1 Modulates SpA-Inhibited Osteogenic Differentiation in Human Bone Mesenchymal Stem Cells [Research Article]


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy